BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 31444018)

  • 1. Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology.
    Chen DY; Huang WK; Chien-Chia Wu V; Chang WC; Chen JS; Chuang CK; Chu PH
    J Formos Med Assoc; 2020 Oct; 119(10):1461-1475. PubMed ID: 31444018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiotoxicities associated with immune checkpoint inhibitors.
    Yang S; Asnani A
    Curr Probl Cancer; 2018 Jul; 42(4):422-432. PubMed ID: 30173878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular toxicities associated with immune checkpoint inhibitors.
    Hu JR; Florido R; Lipson EJ; Naidoo J; Ardehali R; Tocchetti CG; Lyon AR; Padera RF; Johnson DB; Moslehi J
    Cardiovasc Res; 2019 Apr; 115(5):854-868. PubMed ID: 30715219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiotoxicity of Immune Checkpoint Inhibitors.
    Patel RP; Parikh R; Gunturu KS; Tariq RZ; Dani SS; Ganatra S; Nohria A
    Curr Oncol Rep; 2021 May; 23(7):79. PubMed ID: 33937956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiotoxicities of novel cancer immunotherapies.
    Stein-Merlob AF; Rothberg MV; Ribas A; Yang EH
    Heart; 2021 Nov; 107(21):1694-1703. PubMed ID: 33722826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How can we manage the cardiac toxicity of immune checkpoint inhibitors?
    Poto R; Marone G; Pirozzi F; Galdiero MR; Cuomo A; Formisano L; Bianco R; Della Corte CM; Morgillo F; Napolitano S; Troiani T; Tocchetti CG; Mercurio V; Varricchi G
    Expert Opin Drug Saf; 2021 Jun; 20(6):685-694. PubMed ID: 33749484
    [No Abstract]   [Full Text] [Related]  

  • 7. Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity.
    Zarifa A; Lopez-Mattei J; Palaskas NL; Iliescu C; Durand JB; Kim PY
    Adv Exp Med Biol; 2021; 1342():377-387. PubMed ID: 34972975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges and solutions in management of cardiotoxicity induced by checkpoint inhibitors.
    Mladosievičová B; Országhová Z; Jablonická M; Rečková M; Chovanec M; Mego M
    Klin Onkol; 2020; 33(5):350-355. PubMed ID: 33108879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors.
    Dolladille C; Ederhy S; Allouche S; Dupas Q; Gervais R; Madelaine J; Sassier M; Plane AF; Comoz F; Cohen AA; Thuny FR; Cautela J; Alexandre J
    J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31988143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiotoxicity in cancer immune-checkpoint therapy: Mechanisms, clinical evidence, and management strategies.
    Sun JY; Qu Q; Lou YX; Hua Y; Sun GZ; Sun W; Kong XQ
    Int J Cardiol; 2021 Dec; 344():170-178. PubMed ID: 34563597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging role of immune checkpoint inhibitors and their relevance for the cardiovascular system.
    Michel L; Totzeck M; Lehmann L; Finke D
    Herz; 2020 Nov; 45(7):645-651. PubMed ID: 32533218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular Toxicities of Immune Checkpoint Inhibitors: JACC Review Topic of the Week.
    Ball S; Ghosh RK; Wongsaengsak S; Bandyopadhyay D; Ghosh GC; Aronow WS; Fonarow GC; Lenihan DJ; Bhatt DL
    J Am Coll Cardiol; 2019 Oct; 74(13):1714-1727. PubMed ID: 31558256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors.
    Esposito R; Fedele T; Orefice S; Cuomo V; Prastaro M; Canonico ME; Ilardi F; De Stefano F; Fiorillo L; Santoro C; Esposito G
    Biomolecules; 2021 May; 11(6):. PubMed ID: 34067474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do.
    Zito C; Manganaro R; Ciappina G; Spagnolo CC; Racanelli V; Santarpia M; Silvestris N; Carerj S
    Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective cohort study on the cardiotoxicity incidence rates of immune checkpoint inhibitors for oncology patients.
    Ho CC; Wu SL; Tsai HY; Hu YW; Chang YL
    J Chin Med Assoc; 2023 May; 86(5):499-505. PubMed ID: 36872525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Insights into Mechanisms of Immune Checkpoint Inhibitor-Induced Cardiovascular Toxicity.
    Khunger A; Battel L; Wadhawan A; More A; Kapoor A; Agrawal N
    Curr Oncol Rep; 2020 Jun; 22(7):65. PubMed ID: 32514647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure.
    Waliany S; Lee D; Witteles RM; Neal JW; Nguyen P; Davis MM; Salem JE; Wu SM; Moslehi JJ; Zhu H
    Annu Rev Pharmacol Toxicol; 2021 Jan; 61():113-134. PubMed ID: 32776859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Checkpoint Inhibitors and Cardiotoxicity: A Comparative Meta-Analysis of Observational Studies and Randomized Controlled Trials.
    Sharma A; Alexander G; Chu JH; Markopoulos A; Maloul G; Ayub MT; Fidler MJ; Okwuosa TM
    J Am Heart Assoc; 2024 May; 13(10):e032620. PubMed ID: 38761070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitors and cardiovascular toxicity.
    Lyon AR; Yousaf N; Battisti NML; Moslehi J; Larkin J
    Lancet Oncol; 2018 Sep; 19(9):e447-e458. PubMed ID: 30191849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors.
    Baik AH; Tsai KK; Oh DY; Aras MA
    Clin Sci (Lond); 2021 Mar; 135(5):703-724. PubMed ID: 33686402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.